Practical Considerations For individuals experiencing pelvic floor dysfunction who are also managing obesity or type 2 diabetes, semaglutide may offer a multifaceted approach to health improvement
The absence of a gallbladder does not alter the pharmacological action of these injections once they enter your circulation
FDA has documented adverse events including overdoses from dosing errors - get explicit measurement guidance from provider before first injection FTC precedent: FTC December 2025 NextMed enforcement action involved undisclosed GLP-1 subscription costs
While not all gallbladder problems in semaglutide users are directly related to the medication, the possibility of a drug-induced effect on gallbladder function warrants consideration, particularly in individuals with no prior history of gallbladder disease
Promising efficacy so far: Mid-stage trials show large average weight reductions and metabolic improvements, but phase 3 data are still pending
Injection site selection The preferred injection site depends on the treatment goal